IRWDIRONWOOD PHARMACEUTICALS, INC.Small cap · $693.0M · TTM ending 2026-03-31
$4.21-5.82% · 2026-07-13 · EOD
57/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality83
margins & F-ScoreValue72
P/E 7.0 · 75% of 12-mo rangeMomentum71
golden · price above 200-daySmart Money3
selling · 0 funds · 0P/9S insidersBullish stackGolden crossAbove 200-day
vs S&P 500-2.9%
6-mo excess Trailing performance1M +25.7%
3M +16.0%
6M +5.8%
YTD -1.4%
1Y +442.6%
P/E vs its last 12 months (our price history): 1.1 low → 9.0 high
Current price sits at the 75th percentile of that window — near the top (richer). We only compare against the price history we own (no paid multi-year multiples — nothing invented).
Piotroski F6/9
fundamental strength Altman ZDistress
bankruptcy zone ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of 45%. Trailing-twelve-month figures from SEC XBRL.
Dividend & capital return
Shareholder yield18.2%
dividends + buybacks Trailing figures from SEC cash-flow statements. Shareholder yield = total cash returned ÷ market cap.
Net selling0P / 9S insiders · 0 funds hold · 0 Congress buys
Recent insidersSilver Ronald · PFO & PAOSELL$578,063
McHugh Julie · DirectorSELL$80,460
DENNER ALEXANDER J · DirectorSELL$20.5M
Silver Ronald · Principal Accounting OfficerSELL$90,206
Chealth · 64/100
Self-fundingSelf-funding — profitable · generates cash
- ●Bankruptcy-risk zone Altman Z-Score is in the distress zone (-3.61).
- ●One-sided insider selling 9 insider sales and no open-market buys in the recent window.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.